dornase alfa


Also found in: Dictionary, Wikipedia.
Related to dornase alfa: Pulmozyme, cystic fibrosis

dornase alfa

 [dor´nāz al´fah]
recombinant human deoxyribonuclease I (DNase I) used to reduce the viscosity of sputum in cystic fibrosis patients; administered by inhalation.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

dornase alfa

Pulmozyme

Pharmacologic class: Recombinant human deoxyribonuclease I

Therapeutic class: Cystic fibrosis agent, mucolytic enzyme, respiratory inhalant

Pregnancy risk category B

Action

Selectively cleaves to DNA in sputum, decreasing viscosity of pulmonary secretions

Availability

Inhalation solution: 2.5-mg ampule (1 mg/ml)

Indications and dosages

To reduce respiratory tract infections and improve pulmonary function in patients with cystic fibrosis

Adults and children: One ampule (2.5 mg) inhaled once daily; some patients may benefit from twice-daily dosing. Safety and efficacy of daily administration haven't been demonstrated for longer than 12 months.

Contraindications

• Hypersensitivity to drug, its components, or products derived from Chinese hamster ovary cells

Precautions

Use cautiously in:

• pregnant or breastfeeding patients.

Administration

• Don't shake, dilute, or mix with other drugs.

• Use only with approved nebulizer.

• Discard cloudy or discolored solution.

Adverse reactions

CV: chest pain

EENT: conjunctivitis, rhinitis, pharyngitis, hemoptysis, voice changes

Respiratory: dyspnea, increased sputum, wheezing

Skin: rash, urticaria, pruritus

Other: hypersensitivity reactions

Interactions

None known

Patient monitoring

• Assess patient periodically. Report improvement in dyspnea and sputum clearance.

• Monitor for signs and symptoms of hypersensitivity reaction.

Patient teaching

• Teach patient how to use nebulizer.

• Instruct patient to report rash, hives, and itching.

• As appropriate, review all other significant adverse reactions mentioned above.

McGraw-Hill Nurse's Drug Handbook, 7th Ed. Copyright © 2013 by The McGraw-Hill Companies, Inc. All rights reserved

dornase alfa

(dôr′nās′ ăl′fə, -nāz′)
n.
A genetically engineered enzyme used to hydrolyze the DNA in bronchial mucus, facilitating its expectoration, in the treatment of cystic fibrosis.
The American Heritage® Medical Dictionary Copyright © 2007, 2004 by Houghton Mifflin Company. Published by Houghton Mifflin Company. All rights reserved.

dornase alfa

A drug used to remove sticky and tenacious secretions from the air passages of people suffering from CYSTIC FIBROSIS. A brand name is Pulmozyme.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
The company stated JHL1922 would provide an affordable alternative to dornase alfa, which is indicated for daily administration to improve pulmonary function in cystic fibrosis patients in conjunction with other standard therapies.
Hence, the importance of dornase alfa's mode of mechanism of breaking down extracellular DNA to decrease the viscosity of mucus.
M2 EQUITYBITES-December 21, 2017-JHL submits clinical trial application with the Dutch Healthcare Authority for proposed clinical trial of Dornase Alfa Biosimilar in the Netherlands
M2 PHARMA-December 21, 2017-JHL submits clinical trial application with the Dutch Healthcare Authority for proposed clinical trial of Dornase Alfa Biosimilar in the Netherlands
The two most common mucolytics on the market today are dornase alfa (Pulmozyme) and N-acetylcysteine (NAC), commonly referred to as Mucomyst.
Sales of Pulmozyme(R) (dornase alfa) Inhalation Solution were $30.0 million in the third quarter of 2000 compared to $27.0 million in the third quarter of 1999.
Genentech Inc.'s Pulmozyme (dornase alfa) represents the first new approach in 30 years to treating cystic fibrosis.
Sales of Pulmozyme(R) (dornase alfa) Inhalation Solution decreased to $26.8 million in the first quarter of 2000 compared to $28.2 million in the first quarter of 1999 primarily due to fluctuations in timing of orders and the impact of recording a provision against sales related to a packaging defect.